MeiraGTx Holdings Plc is a pharmaceutical company based in the United States. With a ESG score of 28.9, it is considered to be at a medium risk level. Specializing in gene therapy, MeiraGTx focuses on treating eye, salivary gland, and central nervous system disorders. Their portfolio includes innovative products such as AAV-CNGB3, AAV-CNGA3, and AAV-RPGR. Operating in multiple countries including the United States, the United Kingdom, and the European Union, MeiraGTx is dedicated to advancing healthcare through sustainable practices.